<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; driven</title>
	<atom:link href="http://www.tapanray.in/tag/driven/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The AI imperative: Propels Purpose-driven Leaders Revolutionizing Patient Care</title>
		<link>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care</link>
		<comments>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/#comments</comments>
		<pubDate>Fri, 17 May 2024 07:55:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[imperative]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[PDL]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10864</guid>
		<description><![CDATA[The winds of change are blowing in healthcare! Artificial Intelligence (AI) is poised to revolutionize how we deliver quality care to everyone. As a recent ET Healthworld article (March 3, 2024) aptly stated: &#8220;AI and technology are going to be transformative. The only way we can provide &#8230; <a href="http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Keep Pace with Pharma’s Even Nuanced Technology Driven Changes &#8211; For Success</title>
		<link>http://www.tapanray.in/keep-pace-with-pharmas-even-nuanced-technology-driven-changes-for-success/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=keep-pace-with-pharmas-even-nuanced-technology-driven-changes-for-success</link>
		<comments>http://www.tapanray.in/keep-pace-with-pharmas-even-nuanced-technology-driven-changes-for-success/#comments</comments>
		<pubDate>Mon, 14 Nov 2022 00:06:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[blessings]]></category>
		<category><![CDATA[burden]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[flexibility]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[nuanced]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Place]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[way]]></category>
		<category><![CDATA[work]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10725</guid>
		<description><![CDATA[Since 2020, unprecedented global disruptions affecting lives, livelihoods, and business, have impacted India in equal measure, if not more &#8211; across various areas, including the pharma industry. If there is one change that is creating a snowballing effect, is the &#8230; <a href="http://www.tapanray.in/keep-pace-with-pharmas-even-nuanced-technology-driven-changes-for-success/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/keep-pace-with-pharmas-even-nuanced-technology-driven-changes-for-success/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid Prompts Pharma To Move Away From Competition Driven Business Model</title>
		<link>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-prompts-pharma-to-move-away-from-competition-driven-business-model</link>
		<comments>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/#comments</comments>
		<pubDate>Mon, 26 Oct 2020 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[dying]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-serving]]></category>
		<category><![CDATA[solo]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trademark]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10304</guid>
		<description><![CDATA[As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a &#8230; <a href="http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Purpose-Driven-Brands To Win Marketing Warfare In The New Reality</title>
		<link>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality</link>
		<comments>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/#comments</comments>
		<pubDate>Mon, 05 Oct 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[democratize]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[new reality]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven-brands]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefinition]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[warfare]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10286</guid>
		<description><![CDATA[As we navigate through the Covid days, the hope of somehow getting back to the pre-pandemic normal still lingers – notwithstanding a host of uncertainties in its way. The longing is driven by the hype of availability of scientifically proven, safe and &#8230; <a href="http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Union Budget 2018: The &#8216;WOW&#8217; Moment for Indian Healthcare?</title>
		<link>http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=union-budget-2018-the-wow-moment-for-indian-healthcare</link>
		<comments>http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/#comments</comments>
		<pubDate>Mon, 05 Feb 2018 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[2019]]></category>
		<category><![CDATA[ABP]]></category>
		<category><![CDATA[Ayushman Bharat Program]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[centers]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[HCP]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HPS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Subject]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[wellness]]></category>
		<category><![CDATA[WOW]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8825</guid>
		<description><![CDATA[The 2018-19 Union Budget proposals, presented before the Parliament on February 01, 2018. Especially for those who take keen interest in the Indian healthcare environment, was there a ‘WOW’ moment in the budget? Some say, this long-awaited moment came with &#8230; <a href="http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drugs &amp; Devices: Chasing Never-Enough Profit And Price Control</title>
		<link>http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drugs-devices-chasing-never-enough-profit-and-price-control</link>
		<comments>http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/#comments</comments>
		<pubDate>Mon, 25 Jul 2016 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIIMS]]></category>
		<category><![CDATA[angioplasty]]></category>
		<category><![CDATA[CAD]]></category>
		<category><![CDATA[Cardio]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[coronary]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[Devices]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[never-enough-pr0fit]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vascular]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7732</guid>
		<description><![CDATA[On July 20, 2016, the Union Ministry of Health of India announced the addition of Coronary Stents to the National List of Essential Medicines (NLEM) 2015 with immediate effect, bringing them under the Drug Price Control Order. Reacting sharply to &#8230; <a href="http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
